Detalhe da pesquisa
1.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer
; 129(15): 2308-2320, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078412
2.
Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen.
Psychooncology
; 27(1): 354-358, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28181721
3.
Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers.
Transplant Cell Ther
; 28(3): 165.e1-165.e9, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34875403
4.
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077513
5.
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
J Immunother Cancer
; 6(1): 35, 2018 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29754585
6.
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
J Immunother Cancer
; 6(1): 137, 2018 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514386
7.
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Blood Adv
; 7(11): 2360-2363, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36315007